Directed Fusion of Mesenchymal Stem Cells with Cardiomyocytes via VSV-G Facilitates Stem Cell Programming by Kouris, Nicholas A. et al.
Hindawi Publishing Corporation
Stem Cells International
Volume 2012, Article ID 414038, 13 pages
doi:10.1155/2012/414038
Research Article
Directed Fusion of Mesenchymal Stem Cells with
CardiomyocytesviaVSV-G Facilitates StemCellProgramming
Nicholas A. Kouris,1 Jeremy A. Schaefer,1 MasatoHatta,2 Brian T. Freeman,1
Timothy J. Kamp,3 YoshihiroKawaoka,2 andBrenda M.Ogle1,4,5
1Department of Biomedical Engineering, University of Wisconsin at Madison, Madison, WI 53706, USA
2Department of Pathobiological Sciences, University of Wisconsin at Madison, Madison, WI 53711, USA
3Department of Medicine, University of Wisconsin at Madison, Madison, WI 53706, USA
4The Laboratory for Optical and Computational Instrumentation, University of Wisconsin at Madison, Madison,
WI 53706, USA
5The Material Sciences Program, University of Wisconsin at Madison, Madison, WI 53706, USA
Correspondence should be addressed to Brenda M. Ogle, ogle@wisc.edu
Received 19 January 2012; Accepted 22 February 2012
Academic Editor: Selim Kuc ¸i
Copyright © 2012 Nicholas A. Kouris et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Mesenchymal stem cells (MSCs) spontaneously fuse with somatic cells in vivo, albeit rarely, and the fusion products are capable
of tissue-speciﬁc function (mature trait) or proliferation (immature trait), depending on the microenvironment. That stem
cells can be programmed, or somatic cells reprogrammed, in this fashion suggests that stem cell fusion holds promise as a
therapeutic approach for the repair of damaged tissues, especially tissues not readily capable of functional regeneration, such
as the myocardium. In an attempt to increase the frequency of stem cell fusion and, in so doing, increase the potential for cardiac
tissue repair, we expressed the fusogen of the vesicular stomatitis virus (VSV-G) in human MSCs. We found VSV-G expressing
MSCs (vMSCs) fused with cardiomyocytes (CMs) and these fusion products adopted a CM-like phenotype and morphology in
vitro. In vivo, vMSCs delivered to damaged mouse myocardium via a collagen patch were able to home to the myocardium and
fuse to cells within the infarct and peri-infarct region of the myocardium. This study provides a basis for the investigation of the
b i o l ogi c a li m p acto ff u s i o no fs t e mc ell swi t hC M sin vivo and illustrates how viral fusionproteins might better enable such studies.
1.Introduction
Mesenchymal stem cells (MSCs) show promise for thera-
peutic recovery of function of damaged myocardium [1–
5]. MSCs home to injured tissues [6, 7] and contribute to
the structure or functional recovery of the myocardium via
(1) secretion of paracrine factors that can inhibit immune
responses [8] and/or facilitate angiogenesis [7, 9, 10], (2)
transdiﬀerentiation/metaplasia [11, 12], and (3) nuclear
reprogramming through fusion with resident cardiomy-
ocytes(CMs)[13].Thelatterhasbeenlargelydismissedsince
the frequency at which fusion is detected is low relative to
the number of transplanted MSCs. However, recent studies
by us [14] and others [15–17] suggest that despite the low
frequency cell fusion still may exert a dramatic impact on
stem cell programming or reprogramming in the heart.
Cell fate determination was once thought to be uni-
directional [18], that is, as progenitor cells diﬀerentiate
there is a progressive and permanent inactivation of speciﬁc
genes that allow for their potency. However, technological
advances suggest this is not strictly the case. Pioneering
experimentsofnuclearreprogrammingutilizedcellfusionto
demonstratethatcytoplasmicelementsofonefusionpartner
can impact nuclear transcription factors of the other fusion
partner, inducing programming or reprogramming [19–21].
Later studies pinpointed speciﬁc transcription factors that,
when activated exogenously, can fully reprogram somatic
cells to an embryonic-like state [22–26]. Though successful
reprogramming has been realized with this tailored in vitro
approach, programming may require greater temporal con-
trol. Spontaneous physiologic cell-cell fusion is a temporally
and spatially regulated process essential for programming or2 Stem Cells International
diﬀerentiation of certain cell types [27, 28]. Thus cell fusion
mayalsoconferaregulatedtransferoftranscriptionalcontrol
necessary to drive stem cell or progenitor cell diﬀerentiation
for repair of tissues in mature animals.
Cell-cell fusion occurs when the plasma membranes
of neighboring cells fuse to form a multinucleated cell.
To fuse, lipid bilayers of cell membranes must come into
very close contact, in the range of several angstroms. To
achieve this degree of close proximity, the two surfaces must
become at least partially dehydrated as water bound to the
membrane enhances polar repulsion of membranes. Next,
one or both bilayers must be destabilized in some way,
inducing a localized rearrangement of the bilayers. If both
bilayersaredestabilized,anaqueousbridgeisformedandthe
cytoplasmic contents of both cells mix.
Destabilization of membranes can occur as the result of
physical stress (e.g., electrofusion) or chemical interference
(e.g., polyethylene glycol). Electrofusion utilizes short pulses
of electricity to mechanically disrupt the lipid bilayer of a
cell to form pores and if two disrupted membranes come
into contact, cell fusion may occur [29]. Unfortunately, this
process is toxic and the cells must be in contact with one
another at the time the electric ﬁeld is administered. Laser
trapping prior to electrofusion has been used to more eﬀec-
tively position fusion partners, however the process is low
throughput and cytotoxic [30, 31]. A less toxic, but also less
eﬀective and less reproducible approach uses polyethylene
glycol(PEG)[32, 33]. The exact mechanism of PEG-induced
fusion is unknown but is theorized to be due to either local
dehydration leading to unfavorable molecular packing of
the bilayer or to dehydration of the “water shell” near the
lipid bilayer, causing the water molecules between cells to
be displaced, thereby forcing the two membranes together
and subsequently fusing the cells [34]. This technique has
proven useful, but fusion only occurs during the time of
administration of PEG, thus cell delivery with PEG would
induce fusion immediately and nonselectively. A mechanism
that would better regulate fusion either to speciﬁc cells or
speciﬁc regions within tissues is necessary to study fusion in
vivo.
In nature, destabilization of cell membranes and sub-
sequent membrane fusion utilizes the activation of speciﬁc
integral membrane proteins, termed fusogens. The primary
source of information about fusogen architecture, receptor
binding, and activation are from viruses. The most exten-
sively characterized fusogens are inﬂuenza hemagglutinin
(HA) and human immunodeﬁciency virus type 1 envelope
protein (HIV-1 Env). Both fusion peptides are hydrophobic
and require proteolytic cleavage, but HA is activated under
acidic pH during endocytosis, while HIV-1 Env fuses at
neutral pH (reviewed in [35–37]). Less well-studied are the
fusogensrequiredforeukaryoticcellfusionsuchasthefusion
of osteoclasts, myoblasts, and trophoblasts. The greatest
challenge has been establishing which proteins are true
fusogens and which proteins facilitate fusion by placing cells
in close proximity. Many putative fusogens have been shown
to be supporting proteins (i.e., essential for adhesion or
migration). The identiﬁcation of true fusogens is so diﬃcult
that groups have proposed ranking schemes to clarify the
nature and function of these proteins [28]. Because putative
fusogens for spontaneous stem cell fusion have not been
identiﬁed, developing alternative strategies to direct stem cell
fusion could augment our understanding of the biological
impact of such fusion.
Here we utilize viral machinery from vesicular stomatitis
virus(theglycoprotein,VSV-G),oftheRhabdoviridaefamily,
to induce heterotypic fusion between human MSCs and
mouse CMs in vitro and in an in vivo mouse model
of myocardial infarction. Following MSC-CM fusion, we
tracked the phenotype and morphology of fusion products
for one week in vitro and 3 weeks in vivo. VSV-G was
selected because it does not require proteolytic cleavage, is
the sole mediator of receptor binding and fusion, and is pH
dependent [38, 39]. In particular, VSV-G does not require
facilitating proteins to either dock to the host membrane
prior to fusion, or enzymes to prompt the activation of
the fusogen. Furthermore, the pH dependence of VSV-G
is advantageous as the local heart pH after acute ischemic
injury [40–42] is within the acidic range needed to initiate
a conformational change in VSV-G [38, 39]. In this way,
selective activation of VSV-G on transfected MSCs (vMSCs)
at the site of myocardial injury should induce local fusion
in situ, thereby increasing donor cell engraftment and
integration within the tissue and potentially facilitate cardiac
diﬀerentiation.
2.MaterialsandMethods
2.1. Cell Culture. MSCs derived from human embryonic
stem cells (MSCs from WA-09, a gift of Dr. Peiman Hematti)
and HL-1 cardiomyocytes (a gift of Dr. William Claycomb)
were expanded and cultured as previously described [43,44].
B r i e ﬂ y ,M S C sw e r ec u l t u r e do na0 . 1 %g e l a t i n( S i g m a -
Aldrich, St. Louis, MO, USA) pretreated ﬂask containing
α-minimum essential medium- (MEM-) complete. Alpha-
MEM-complete consisted of α-MEM (Invitrogen, Carlsbad
CA, USA), 10% fetal bovine serum (Hyclone, Logan UT),
0.1mM nonessential amino acids (Invitrogen), and 2mM L-
glutamine (Invitrogen). MSC cultures were allowed to grow
to 60–70% conﬂuency and were replated at a concentration
of 1,500cells/cm2. CMs were cultured on ﬁbronectin/gelatin
(1.25mgﬁbronectin/100mL0.02%gelatin)(Sigma-Aldrich)
pretreated ﬂasks containing Claycomb-complete. Claycomb-
complete medium was comprised of Claycomb medium
(SAFC Biosciences, St. Louis, MO, USA), 10% fetal bovine
serum qualiﬁed for CMs (SAFC Biosciences), 100U/mL:
100μg/mL penicillin-streptomycin (Lonza, Walkersville,
MD, USA), 0.1mM norepinephrine (Sigma-Aldrich), and
2mML-glutamine(Invitrogen).CMswerepassagedat100%
conﬂuence and split 1:2. Experiments were performed using
passages 7–10 and 60–110 for MSCs and CMs, respectively.
All cultures were maintained at 37◦Ci n5 %C O 2.
2.2. Transfection and Analysis. MSCs were transfected with a
pCVSV-G-1 plasmid [45]t h a te n c o d e sV S V - Gu n d e raC A G
promoter using the Neon Transfection System (Invitrogen),
according to manufacturer’s protocol. Brieﬂy, 5 × 105 cellsStem Cells International 3
were transfected with 2μg of plasmid with one 1,300V
pulse for 20msec and plated in 6-well plates. To determine
transfection eﬃciency, electroporated cells were cultured for
24h and immunocytochemistry (ICC) was performed to
detect VSV-G protein expression. Brieﬂy, cells were washed
with two rinses and two incubations of 1X PBS. Cell ﬁxation
was performed with 4% PFA, followed by another set
of washes, and probed with the 1:50 dilution of FITC-
conjugatedanti-VSV-Gantibody(GeneTex,SanAntonioTX,
USA) in 3% BSA for 60min. Cultures were washed a ﬁnal
time and mounted in DABCO/DAPI mounting medium
(2.5% 1,4-diazabicyclo[2.2.2]octane (Sigma-Aldrich), 50%
glycerol (Fisher Scientiﬁc, Forest Lawn, NJ, USA), and
0.005% 4 ,6-diamidino-2-phenylindole (Sigma-Aldrich) in
PBS). The transfection eﬃciency was calculated as the
number of cells positive for VSV-G (green) divided by the
total number of cells. To determine if the cell dissociation
reagent altered VSV-G expression, duplicate VSV-G trans-
fected MSC (vMSC) cultures were harvested with 0.25%
trypsin (Mediatech, Inc. Manassas, VA, USA) or 1X Accutase
(Innovative Cell Technologies, Inc. San Diego, CA, USA)
containing 0.5mM EDTA, inactivated with culture medium,
washed with 1X PBS, probed with the anti-VSV-G antibody
(as above), and washed a ﬁnal time with 1X PBS. vMSCs
were analyzed via FACSCalibur (BD Biosciences San Jose,
CA, USA) at the University of Wisconsin Carbone Cancer
Center Flow Cytometry Facility (UWCCC).
2.3.FlowCytometryAnalysis. VSV-Gexpressionlevelpercell
was determined using the Quantum MESF kit (Molecules of
Equivalent Soluble Fluorochrome, Bangs Laboratories, Inc.
Fishers, IN) and FACSCalibur cytometer (BD Biosciences).
The Quantum MESF kit consists of 5 populations of micro-
spheres with increasing surface-labeled ﬂuorochrome, which
have been standardized to speciﬁc concentrations of pure
ﬂuorophore per microsphere. Each population was analyzed
via ﬂow cytometry and a standard curve was generated by
plotting population (i.e., concentration of ﬂuorophore per
microsphere) versus intensity. QuickCal software was used
to verify the linearity of the standard curve. Next, vMSCs
and corresponding control populations were labeled with an
anti-VSV-G-FITC antibody and analyzedvia ﬂow cytometry.
Using the standard curve and the measured intensity value
for vMSC populations and corresponding controls, the
number of ﬂuorophores per cell was determined. This value
wasdividedbytheaveragenumberofﬂuorophores(4.2)that
bind to a single antigen to determine the number of proteins
expressed per cell. Ten thousand cells and three replicates
were analyzed per population. Populations included vMSCs
with anti-VSV-G antibody, MSCs with anti-VSV-G antibody
and vMSCs without antibody.
2.4. Cell Fusion Induction. To determine if vMSCs fuse
more readily with cardiomyocytes than untreated MSCs,
vMSCs and MSC controls were cocultured with CMs and
analyzed for incidence of fusion. To distinguish cell types
in cocultures, MSCs and CMs were stained with 1μmC e l l -
Tracker Green CMFDA and 20μm Red CMTPX (Molecular
Probes Eugene, OR, USA), respectively, according to the
manufacturer’s protocol. Following labeling, 5 × 105 CMs
were plated and cultured for 4h followed by the addition
of 1.5 × 105 MSCs or vMSCs per well in 6-well plates
(BD Biosciences). After 14h of coculture, suspensions were
washed with 1X PBS and then bathed for 2min in fusion
media [46] of varying pH (i.e., pH 5.5, 6.5, or 7.5 that
correspond to active and inactive forms of the VSV-G fusion
protein) adjusted with HCl. For long-term characterization
of fusion products, medium was changed 1 day and 4 days
after coculture.
2.5. Quantiﬁcation of Fusion Products. Cocultures of CMs
with MSCs or vMSCs were maintained in culture medium
for 4h after incubation with fusion medium, followed by
imaging and ﬂow cytometry. Images were acquired with
a 20X UPlanFluor objective (NA = 0.5), FITC and Texas
Red ﬁlters, on an IX71 inverted deconvolution ﬂuorescence
microscope (Olympus Center Valley, PA, USA) and analyzed
with Slidebook software (Intelligent Imaging Innovations
Denver, CO, USA) and ImageJ (Fiji; open source software,
http://paciﬁc.mpi-cbg.de/wiki/index.php/Fiji). Images were
normalized using unstained controls. Cells were analyzed at
the UWCCC Flow Cytometry Facility on a FACSCalibur ﬂow
cytometer(BDBiosciences).Eventswerelive/deadgatedwith
forward scatter and side scatter plots. Fusion products were
quantiﬁed by gating the region positive for FL1 and FL2
channels, corresponding to CellTracker Green CMFDA and
Red CMTPX, respectively.
2.6. Optical Analysis of Cell and Fusion Product Phenotype.
MSCs or CMs in monolayer were stained for proteins
characteristic of MSCs (CD73, CD90, and CD105), as well as
proteins characteristic of CMs (sarcomeric myosin (MF20)).
Cell cultures were ﬁxed with 4% paraformaldehyde for
10min, followed by two washes with phosphate buﬀered
saline (Fisher Scientiﬁc). Cells were probed with goat anti-
CD73 (V-20, Santa Cruz Biotech, Santa Cruz, CA, USA),
rabbit anti-CD90 (RB3970, Abgent, San Diego, CA, USA),
goat anti-CD105 (GKY02, R&D Systems, Minneapolis, MN,
USA), and mouse anti-MF20 (IgG2b, Developmental Stud-
ies Hybridoma Bank, Iowa City, IA) diluted 1:25, 1:50,
1:50, and no dilution, respectively, in diluting buﬀer (5%
BSA (Fisher Scientiﬁc), 0.02% NaN3- (Acros Organics) in
phosphate buﬀered saline (Fisher Scientiﬁc)) and incubated
for 30min at room temperature or overnight at 4◦C, fol-
lowed by incubation with ﬂuorescent secondary antibodies:
donkey anti-goat Alexa Fluor (AF488, Invitrogen), goat
anti-rabbit Alexa Fluor (AF647, Invitrogen), and donkey
anti-mouse (AF546, Invitrogen) at a 1:200 dilution in
preadsorption solution (90% diluting buﬀer, 5% human
serum (Pelfreez, Brown Deer, WI, USA), and 5% mouse
serum (Equitech-Bio, Inc, Kerrville, TX, USA)) for 45min
at room temperature. Samples were counterstained with
DABCO/DAPI mounting solution. Fluorescence emission
wasdetectedonanIX71inverteddeconvolutionﬂuorescence
microscope (Olympus). Images were acquired with a 20X
UPlanFluor objective (NA = 0.5), and analyzed using4 Stem Cells International
Slidebook software (Intelligent Imaging Innovations Denver,
CO, USA) and with ImageJ (Fiji; open source software,
http://paciﬁc.mpi-cbg.de/wiki/index.php/Fiji). Images were
thresholded to a secondary antibody only control. Validation
of method is shown in Supplementary Figure 1A available
online at doi:10.1155/2012/414038.
MSC-CM or vMSC-CM cocultures were probed with
antibodies against CM marker (MF20) and MSC marker
(CD105) to evaluate the morphology of fusion products and
the phenotype of cells within coculture. Positive events for
fusion were calculated as the percentage of CD105 and MF20
positive cells containing a nucleus divided by total number
of nuclei obtained from analysis of at least eight optical ﬁelds
per sample. Fields (3–10 ﬁelds) were selected based on cell
number (minimum of 3 cells) and position within the wells
(center of wells) n = 2.
2.7. Induction of Myocardial Infarction in Mice. Myocardial
infarction was induced in C57BL/6 mice (Jackson Labora-
tory, Bar Harbor, ME, USA) by left coronary artery ligation
aspreviouslydescribed[47,48]andasisroutinelyperformed
in the University of Wisconsin Cardiovascular Physiology
Core Facility. All animal procedures were performed in
accordance with the guidelines of the American Associa-
tion for Laboratory Animal Science and the University of
Wisconsin-Madison Animal Care and Use Committee.
2.8. Delivery of MSCs or vMSCs via the TissueMend Matrix
to the Murine Myocardium. TissueMend (TEI Biosciences)
was prepared and cells were seeded as previously described
[48]. Brieﬂy, TissueMend matrices (2mm × 2mm ×
0.8mm) were placed in wells of 24-well plates containing α-
MEM-complete culture medium. Following electroporation,
vMSCs were seeded on the TissueMend sections at a concen-
tration 3 times greater than MSCs (cell control due to 30%
cell viability after electroporation, yielding 1 × 106 cells/mL.
Medium was changed at 24 and 48h, at which point the
TissueMend matrix containing ∼2.3 × 104 MSCs, vMSCs, or
unseeded (matrix control) was tacked to the myocardium at
each corner of the matrix. The matrix was placed such that
it was in contact with both the infarct and the peri-infarct
regions of the myocardium [48].
2.9. Optical Analysis of Heart/Tissue Explants. Murine hearts
were harvested three weeks after matrix implantation to
assess the occurrence and, if detected, the frequency of in
vivo fusion. Hearts were bisected longitudinally through
the matrix. The tissues were immediately placed into 10%
buﬀered formalin (pH = 7.2; Fisher Scientiﬁc) for 24h
followed by 24h of fresh 10% buﬀered formalin, and a ﬁnal
24h of 70% ethanol. Samples were further processed for
paraﬃn embedding and sectioning as previously described
[49]. Fluorescent in situ hybridization (FISH) tissue diges-
tion kit with all human centromere probe (red) and all
mouse centromere probe (green) (Kreatech, Amsterdam,
the Netherlands) was performed on sections to detect
fusion events. Samples were processed by the Cytogenetics
Laboratory (WiCell Research Institute, Madison, WI, USA)
according to manufacturer’s protocol. Brieﬂy, slides with
paraﬃn embedded sections were baked for 4h at 56◦C.
Specimens were incubated with pepsin for 70min for tissue
digestion prior to sequential hybridization of the human
probe followed by mouse probe. Images were acquired with
a 60X UPlanSApo (NA = 1.35 Oil), DAPI, Green, and
Orange ﬁlters, on an Olympus BX41 Upright Fluorescence
Microscope (Olympus Valley, PA, USA), and analyzed with
FISHView Version 5.5 software (Applied Spectral Imaging,
Vista CA). Fusion events were deﬁned as nuclei with positive
staining for both human centromeres (red) and mouse
centromeres (green). The frequency of fusion events was
reported as the number of fusion events per total nuclei
for a given region of the heart tissue: myocardium (myo),
myocardial infarct (MI), border region (border), within
Tissuemend patch (TM), and in the healthy myocardium
(healthy). Five to twelve ﬁelds were selected for each location
and the number of hearts analyzed were, n = 1 for TM only
and n = 3f o rT M+v M S C .
2.10. Statistical Analysis. For comparison of VSV-G expres-
sion, fusion frequency, and fusion product morphology
versus controls, a normal distribution was assumed and one-
way analyses of variance and Student’s t-test were used. Data
were analyzed with Microsoft Excel (Microsoft, Redmond,
WA, USA).
3. Results
3.1. Expression of VSV-G in MSCs. MSCs were induced
to express VSV-G via transfection by electroporation. Low
transfection eﬃciency would limit the ability of VSV-G to
promote fusion and so VSV-G expression on MSCs was
determined following electroporation. Twenty-four hours
after transfection control MSCs and MSCs transfected
with VSV-G (vMSCs) were probed with an anti-VSV-G
antibody conjugated to ﬂuorescein isothiocyanate (FITC)
and visualized with ﬂuorescence microscopy to determine
the percentage of cells expressing VSV-G. The average
transfection eﬃciency was 32% ± 5% (n = at least 6 optical
ﬁelds per sample per trial for 3 trials, Figure 1(a)). Since
vMSCs will be harvested for in vivo studies, we also assessed
VSV-G expression via ﬂow cytometry after removal from
culture plates with trypsin. We found expression of VSV-
G plummeted to 5% ± 2% (n = 1 replicate per sample
p e rt r i a lf o r3t r i a l s ,F i g u r e1(b)). This is perhaps not
surprising as others have reported decreased stability of
VSV-G with trypsin treatment [50, 51]. Trypsin is a serine
protease that cleaves carboxyl groups on the cell surface
to remove cells from a culture surface. VSV-G is a cell
surface protein that would be exposed to the dissociation
reagent [52]. The disruption to VSV-G by trypsin was
corroborated by evaluating the number of VSV-G proteins
per cell. The administration of trypsin signiﬁcantly reduced
the number of VSV-G proteins on the cell surface of vMSCs
(Figure 1(d)). Thus we replaced trypsin with Accutase,
a mixture of proteases and collagenases that has been
shown to improve cell viability compared to trypsin [53].Stem Cells International 5
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Figure 1: Expression of VSV-G in MSCs. VSV-G expression was analyzed via immunoﬂuorescence using an anti-VSV-G-FITC antibody.
(a) Representative image analysis of untransfected MSCs and vMSCs; VSV-G (green); DAPI (blue). Scale bar = 25μm. (b) Transfection
eﬃciency was deﬁned as the number of VSV-G-positive cells divided by the total number of nuclei and is reported as the mean ± standard
deviation. A low level of nonspeciﬁc binding was associated with the anti-VSV-G antibody and is reﬂected in the percentage of positive cells
reported in the untransfected population of MSCs (2.3% ± 3.4%). (c) Dissociation reagent impacts VSV-G expression. Trypsin treatment
reduces detection of VSV-G expressing cells to that of untransfected MSCs. Accutase treatment retains a signiﬁcantly greater number of cells
expressing VSV-G than treatment with trypsin;
∗∗P < 0.005. (d) Dissociation reagent impacts the number of VSV-G proteins per cell. The
number of VSV-G proteins expressed per cell is signiﬁcantly reduced with trypsin treatment as compared with Accutase treatment, which
was quantiﬁed utilizing Quantum Simply Cellular standards;
∗∗P < 0.005.
With Accutase treatment, the average number of cells ex-
pressing VSV-G after cell harvest was 21%±7%, a signiﬁcant
improvement over treatment with trypsin and at a level high
enough to discern whether expression of VSV-G can impact
MSC-CM fusion (n = 1 replicate per sample per trial for 3
trials).
Fusogens such as VSV-G are most potent on the cell
surface when there are adequate amounts of protein to fa-
cilitate fusion, but a low enough amount to avoid immune
responses. Thus VSV-G protein expression per cell was
determined using aQuantum MESF kit (BangsLaboratories,
Inc.), on the FACSCalibur. Using this method, the average
number of VSV-G proteins per cell was 8 × 104 ± 2 × 104
with trypsin and 1 × 106 ± 8 × 103 with Accutase (n = 1
replicate per sample per trial for 3 trials, Figure 1(c)). Thus,
allfurtherexperimentswereperformedusingAccutaseasthe
dissociation reagent to prevent VSV-G cleavage.
3.2.VSV-GMediatesStemCellFusion. Todeterminewhether
MSCs expressing VSV-G are better equipped to fuse with
CMs than unmanipulated counterparts, vMSCs or MSCs
were cocultured with CMs. To distinguish cell types in
cocultures, MSCs and vMSCs were stained with Red Cell-
Tracker, while CMs were stained with Green CellTracker
ﬂuorescent probes prior to being combined. Since VSV-G
undergoes a conformational change from its inactive form
to its active form at pH < 6.2 [54, 55], cocultures were
brieﬂy incubated (2min) with fusion medium of pH = 5.5.
Image analysis of vMSC-CM cocultures treated with fusion
medium of pH = 5.5 revealed cells with colocalization of6 Stem Cells International
green and red ﬂuorescence, indicating fusion events, while
MSC-CM cocultures under the same pH condition exhibited
limited colocalization (Figure 2(a)). To accurately assess
the amount of cell fusion, cocultures were harvested 24
hours after seeding and analyzed via ﬂow cytometry (double
positive cells correspond to fusion events). vMSCs treated
with acidic medium (pH 5.5) had signiﬁcantly higher rates
of fusion with CMs (4.7% ± 1.1%) than MSCs treated
in the same way (i.e., spontaneous fusion, 1.4% ± 0.2%)
(P<0.05) (Figure 2(b)). Further, the percentage of fusion
products identiﬁed in vMSC-CM cocultures exposed to
fusionmediumofpH =6.5or7.5(maintainingVSV-Ginthe
inactive form) did not diﬀer from MSC-CM cultures (n = 3
replicates per sample per trial for 3 trials, Figure 2(c)).
3.3. Impact of Microenvironment on Phenotype of MSC-
CM Fusion Products. Many studies have demonstrated that
stem cell programming is inﬂuenced by the microenviron-
ment [56–58]. To determine whether the phenotypic fate
of vMSC-CM fusion products could be regulated by the
microenvironment, following treatment with fusion media,
we cultured vMSC-CM fusion products under either MSC-
speciﬁc or CM-speciﬁc culture conditions and examined the
incidence of fusion and morphology of MSC-CM fusion
products. At days 5 and 7 following the induction of cell
fusion, cocultures were probed with CM and MSC speciﬁc
antibodies (anti-MF20 and anti-CD105, respectively, n = 1
replicate per sample per trial for 3 trials). At day 5, vMSC-
CM cocultures contained a relatively high number of cells
that expressed both MF20 and CD105 and the percentage
of MF20+/CD105+ cells relative to the total cell number was
signiﬁcantly greater than that of MSC-CM cocultures for
both culture conditions (P<0.005) (Figure 3(a)). Of note,
the percentage of MF20+/CD105+ cells was much higher
than the percentage of double positive cells detected using
CellTracker dyes and ﬂow cytometry (Figure 2(b)). This
could reﬂect the loss of VSV-G sustained by cell harvest,
the diﬀerent analytical approach (i.e., ﬂow cytometry versus
image analysis) and/or the behavior of fusion products
between day 1 and day 5 (i.e., proliferation). By day 7, the
percentage of MF20+/CD105+ cells decreased to levels not
statistically diﬀerent from controls for both culture condi-
tions. At the same time, the number of cells expressing MF20
aloneincreasedsubstantiallyforbothcultureconditions.The
change in percentage of MF20+/CD105+ cells from day 5 to
day7couldreﬂectdeathoffusionproducts,orprogramming
of the MSC fusion partner to a cardiomyocyte phenotype
or both. If death of fusion products occurred, one would
expect unfused CMs and MSCs to proliferate to ﬁll the voids
of the culture space. Interestingly, only the CM population
increased from day 5 to day 7 and at rates signiﬁcantly
higher than that of control cultures, suggesting at least a
portion of fusion products were maintained, and ultimately
adopted a cardiomyocyte-like phenotype. This result was
observed independent of the culture conditions. Of note,
this experimental approach does not exclude the possibility
that metaplasia rather than fusion occurred, that is, MSCs
diﬀerentiate into CMs as a consequence of soluble factors
in the coculture medium and maintain (at least transiently)
expression of each cell type. However, MF20+/CD105+ cells
were rare in MSC-CM cocultures, suggesting metaplasia
alone cannot account for coexpression of MF20+/CD105+
or subsequent loss of MF20+/CD105+ cells. In addition,
MF20+/CD105+ cells exhibited two distinct morphologies;
some were long and spread, displaying MSC-like morphol-
ogy (MSC medium = 16.59% ± 6.32%; CM medium =
14.03% ± 1.59%) while the majority (P<0.05) were round
and cobblestone-like, indicative of CM-like morphology
(MSCmedium =80.49%±10.45%;CMmedium =85.97%±
1.60%) (Figures 3(b) and 3(c), Supplementary Figure 1B).
These results further support the possibility that CM
nuclear material and cytoplasmic elements direct program-
ming of MSC-CM fusion products independent of culture
conditions.
3.4. vMSCs Fuse In Vivo. To determine whether MSCs ex-
pressing VSV-G could fuse with cardiac cell types in vivo,
vMSCs were delivered to the damaged myocardium via a
TissueMend patch. We have previously demonstrated that
MSCs delivered in this way are maintained in the patch
and in the tissue between the patch and the myocardium
up to 3 weeks after delivery at higher percentages than
with conventional delivery modalities [48]. Furthermore,
Laﬂamme et al. have found one of the major factors for
cell loss during transplantation is anoikis [59], and thus
providing anchorage support to transplanted cells increases
viability and retention. In this study, we sought to determine
whether VSV-G expressing MSCs (donor) would be able to
migrate to the damaged myocardium and fuse with recipient
cardiac cell types. Thus, one day following induction of
infarction via ligation of the left anterior descending artery,
a patch containing vMSCs was applied to the heart in
contact with healthy and damaged tissue. Three weeks
after cell transplantation, heart excision, and histology
were performed on left ventricular tissue as previously
reported [48]. Histological sections were probed using FISH
for human-speciﬁc and mouse-speciﬁc centromeres and
all nuclei containing both probes were considered fusion
products. Human cells were found in the TissueMend patch
and in the “border region” (the area between the patch and
the myocardium). Donor-host cell fusion was evident in the
TissueMend patch, the border zone, and in the infarcted
myocardium of hearts receiving TissueMend with vMSCs.
No human cells or fusion products were found in the healthy
cardiac tissue of hearts receiving TissueMend with vMSCs.
Inaddition,nohumancellsorfusionproductswerefoundin
theTissueMendpatch,borderzoneorinfarctedmyocardium
of hearts receiving TissueMend only. In regions of hearts
receiving TissueMend with vMSCs and selected for high
density of fusion events, the frequency of cell fusion relative
to the total number of nuclei in a given region was 22% ±
16%,TissueMendpatch(n = 3hearts,12ﬁelds);14%±10%,
border zone (n = 3h e a r t s ,5ﬁ e l d s ) ;1 9 %± 10%, infarcted
myocardium (n = 3 hearts, 8 ﬁelds). Though these levels
represent the maximum amount of fusion per region, they
are substantially higher than those previously reported forStem Cells International 7
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Figure 2: VSV-G facilitates vMSC-CM fusion. Four hours after pH-induced fusion, samples were harvested and analyzed using ﬂuorescence
deconvolution microscopy and ﬂow cytometry for events displaying both CellTracker ﬂuorescent probes. (a) Representative vMSC-CM
fusion event (white arrow). CMs were labeled with CellTracker green and vMSCs were labeled with CellTracker red. Scale bar = 50μm.
(b) Eﬀect of VSV-G on vMSC-CM fusion at pH = 5.5. Fusion events were increased 3.5-fold with VSV-G at low pH. (c) Eﬀect of pH on
VSV-G-mediated MSC-CM fusion. vMSC-CM fusion was inhibited by pH = 6.5 and 7.5 (inactive form of VSV-G)
∗P < 0.05.
spontaneous fusion following MSC transplantation, wherein
one fusion event per ﬁeld or image containing hundreds
of nuclei was rare [13, 60, 61] (Figure 4). These results
demonstrate that expression of viral fusogen VSV-G can
be used to induce fusion of MSCs, and potentially other
clinically relevant cell types, to enable study of the biologic
and therapeutic impact of cell fusion in the heart.
4. Discussion
Fusion of transplanted stem cells with recipient cardiomy-
o c y t e sh a sb e e no b s e r v e di nm u r i n e[ 13, 60] and porcine
model systems [49]. But since these ﬁrst observations, few
have sought to unravel the mechanisms that govern stem cell
fusion or to study the implications of cell fusion for stem
cell programming. Lack of study reﬂects the overwhelming
opinion that cell fusion occurs too infrequently to be of
relevance for stem cell programming and, by corollary,
for tissue repair. However, this opinion fails to appreciate
the possibility that (1) detection methodologies may be
insuﬃcient to accurately gauge the contribution of cell
fusion following stem cell transplantation and/or (2) that
we might be able to control or increase the frequency of
cell fusion to more eﬀectively induce programming of stem
cells following transplantation. We have begun to explore
thissecondpossibilitybyco-optingthewell-describedfusion
machinery of viruses. We ﬁnd that mesenchymal stem cells
modiﬁed to express viral fusogen VSV-G are more apt to fuse
with cardiomyocytes in a pH-dependent manner. vMSC-
CM fusion products formed in this way are prone to adopt
cardiomyocyte phenotype and morphology. In addition,
vMSCs delivered to the myocardium of mice following
infarction can fuse with resident cardiac cell types at rates
much higher than previous reports of spontaneous fusion
[13, 61] and are more apt to fuse at the site of infarction than
in the healthy myocardium.
Increasing the frequency of MSC-CM cell fusion will aid
in the study of cell fusion in vitro and may improve the ther-
ape u ticbe neﬁto fMSCsinvivo. Onewaythatthetherapeutic
beneﬁt may be improved is via induction of programming of
MSCs to a cardiomyocyte fate. Diﬀerentiation of MSCs into
CMs can be initiated in vitro via soluble factors including
5-azacytidine [62–64] or with exposure to insoluble factors
including laminin [65]. However, functional diﬀerentiation
of MSCs to cardiomyocytes has only been accomplished
to date via cell fusion with mature cardiomyocytes. This
result has been demonstrated in vitro [66]a n din vivo
wherein MSC-CM fusion products take on a cardiomyocyte
morphology, express cardiomyocyte markers, and couple to
adjacent cardiomyocytes [60]. Here we ﬁnd that when MSC-
CM fusion is induced with viral fusogens, the CM fusion
partner is dominant in that the majority of fusion products8 Stem Cells International
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Figure 3: Phenotypic and morphologic characteristics of vMSC-CM fusion products. After pH-induced fusion, fusion products display two
distinct morphologies: CM-like (round) and MSC-like (spread). Fusion products were probed for markers indicative of MSC (CD105) and
CM (MF20) phenotype. (a) MF20+/CD105+ cells are signiﬁcantly increased with vMSCs at day 5 relative to untransfected MSCs, while the
culture environment (MSC medium and CM medium) had no eﬀect on the percent of dual positive events in vMSC-CM cocultures at day 5.
∗P < 0.05. (b) Morphology of MF20+/CD105+ cells was typically CM-like and culture environment did not alter this tendency.
∗P < 0.05.
(c) Representative morphologies of MF20+/CD105+ cells. White arrows indicate MF20+/CD105+ cells. Scale bar = 25μm.Stem Cells International 9
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Figure 4: Fusion of VSV-G-expressing human mesenchymal stem cells (donor) with cardiomyocytes (host) in vivo. (a) Fluorescence in situ
hybridization with species-speciﬁc centromeric probes to detect fusion products in the murine myocardium. Human MSCs (red), mouse
cells (green), all nuclei (blue), and fusion products (FP; red and green signal in the same nucleus) are found within the border and TM
regions, while typically only mouse cells are found in the myocardium, “myo.” Insets display (b) human (arrow) and mouse (arrowhead)
cells, (c) representative fusion product, and (d) fusion product undergoing anaphase, indicative of proliferation.
(regardless of medium type) adopt a CM-like morphology
and maintain expression of MF20 and lose CD105. These
datafurthersupport the exciting possibility thatinduction of
fusionwithviralfusogenscouldenhanceMSCprogramming
to a CM fate in vivo. Of note, the CMs utilized here
are HL-1 CMs. This cell line was used to enable large-
scale and long-term studies. However, the heterogeneity and
immortal nature of these cells may account for the seeming
dominance of the CM phenotype and future studies will
utilize primary fetal cardiomyocytes or induced pluripotent
stem cell-derived cardiomyocytes.
Our results suggest that the diﬀerentiation of MSCs to
a CM fate can be promoted by cell-cell fusion. However,
in certain circumstances in vitro, MSC-CM fusion products
can reenter the cell cycle and proliferate suggesting cell-cell
fusion can also promote reprogramming of the CM [67–69].
Proliferation of fusion products may be as advantageous for
cardiac tissue repair as diﬀerentiation of functional cell types
since more cells could be produced to replace lost cells. In
addition, recent evidence has demonstrated that MSC-CM
fusion includes mitochondrial exchange, which is essential
for somatic reprogramming [69]. Understanding cell-cell
fusion in conjunction with mitochondrial preservation may
provide alternate, simple, and direct mechanisms to rescue
cells following ischemia-induced damage. There is evidence
indicating that the fusion product’s proliferative capacity is
regulated by the stem cell while the developmental direction
is dictated by the somatic cell [70–72], and the combination
of both outcomes presented herein are means to repopulate
the myocardium for functional improvement.
While we have utilized vMSCs to both understand and
exploit the physiological role of MSC-CM fusion, induction
of fusion of another stem cell,progenitor, or even mature cell
types may augment our ability to repopulate and repair the
damaged myocardium [59, 73–79]. In the case of mature or
progenitor cell transplantation, the induction of fusion may
be less beneﬁcial from a diﬀerentiation standpoint and more
beneﬁcial from an engraftment or retention standpoint. One
of the primary challenges for stem cell delivery is the ∼90%
cell loss after transplantation [80–82] that has prompted the
development of new methods to deliver and maintain cells
in the heart [48, 83, 84]. This is particularly problematic for
cardiac therapy as the heart is mechanically active, rapidly
ﬂushing cells from the intended target region. If stem cells
transiently express a viral fusogen, they might rapidly adhere
and so be maintained long term in the heart. The added
advantage of pH sensitive fusogens, such as VSV-G, is the
ability to control activity such that cells only fuse at pH
lower than 6.5. This has major implications for inducing
temporally (the window during ischemia) and spatially (the
ischemic region) regulated fusion in vivo. In fact, vMSCs
delivered to the heart were found in the patch and in
damagedmyocardium fusedwithmousecells.Theability for
VSV-G to induce fusion in the patch may be due to close
proximity to the ischemic region, causing the environment
to be more acidic or by the remodeling of the collagen10 Stem Cells International
patch [48]. Collagen remodeling has been shown to occur
via MSC secretion of matrix metalloproteinases (matrixins),
serineproteases,andcysteineproteases[85].Whilematrixins
are active at neutral pH, serine and cysteine proteases are
active at acidic pH, indirectly demonstrating cells are able to
make the microenvironment acidic [86]. Taken together, the
induction of cell fusion in the heart could exert functional
beneﬁt via multiple mechanisms.
A primary limitation of this approach is introducing
viral machinery to an already damaged recipient. The entire
virion, VSV, is known to be immunogenic and, at high
enough concentrations, is lethal to mice [87]. Puriﬁed VSV-
G or VSV-G reconstituted in lipid bilayers administered
to in vitro cell culture is mitogenic (>0.8μg/mL) [88].
Interestingly,ifthelipidconcentrationswereincreased,while
VSV-G concentration was held constant, the mitogenicity
decreased, suggesting that the spacing of VSV-G in the
membrane plays a role. Conﬁrming the importance of VSV-
G arrangement, Ochsenbein et al. demonstrated that 1,000
times more antibody is produced by C57BL/6 mice against
highly organized VSV-G on the nucleocapsid of intact VSV
versuspoorlyorganizedVSV-Ginmicelles[89].Theamount
of viral proteins we delivered (based on the mass of the
protein [39], the proteins expressed per cell combined with
the number of cells delivered) is 7 orders of magnitude below
the reported amount to elicit an immune response [88]a n d
we express only the fusogen and not the entire virion. Even if
methods were developed to increase expression levels per cell
and/or in combination with high numbers of cells, spacing
could be evaluated to avoid immune responses. However,
based on the reported concentration required to elicit a
response, delivery of vMSCs as prepared in this study would
not trigger a response.
While vMSCs may not be immunogenic, transfection
itself may cause adverse genetic eﬀects. For instance, stable
transfection with most viral systems causes integration of
the gene at a random site in the genome [90–92]. When
mutagenesis occurs, integration may occur at a site that
interferes with cells ability to regulate itself, resulting in
deregulation of proliferation and tumorigenesis [93, 94].
In addition to experimental evidence of malignancy, this
has been seen clinically ([95, 96], reviewed in [97]). Here,
transfectionislargelytransientandonlyrarelyintegratesinto
the genome. Clinical use would require further safeguards,
perhaps including liposomal delivery of the protein.
5. Conclusion
The data presented support the utility of VSV-G-mediated
fusion to study the eﬀects of stem cell fusion on cell repro-
gramming and functional improvement of tissues including
the heart. Future studies may also employ VSV-G to rescue
damaged cells of other ischemic tissues in the body, or
even selectively target cells for destruction. For example, the
microenvironment of tumors and the overactive osteoclasts
in Paget’s disease are below the pH threshold necessary to
activate the conformational change in VSV-G. Local admin-
istration of VSV-G in liposomes containing toxic factors or
highly acidic pH to this microenvironment may fuse with
these poorly regulated cells and dampen their detrimental
eﬀect.
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